Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial Article Swipe
Jung‐Min Lee
,
Austin Miller
,
Peter G. Rose
,
Mariam AlHilli
,
Christina Washington
,
Veena S. John
,
Chirag A. Shah
,
Koji Matsuo
,
Jean Siedel
,
David S. Miller
,
Elizabeth Hopp
,
Andrea O’Shea
,
John K. Chan
,
Leslie Bradford
,
Christopher B. Morse
,
Christa Nagel
,
Kerry J. Rodabaugh
,
Elise C. Kohn
,
Kathleen N. Moore
,
Joyce F. Liu
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.29313370
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.29313370
Supplementary Figure 1. Progression-free survival and overall survival by randomized treatment (N = 120). Distributions were estimated utilizing the Kaplan-Meier method for progression-free survival (PFS) by investigator assessment. Hazard ratios (HR) are estimated with a proportional hazards model stratified by prior PARP inhibitor (yes vs no) and prior immune checkpoint inhibitor (yes vs no). The confidence intervals (CIs) are adjusted to provide 95% simultaneous coverage for the study’s original 4 treatment comparisons. The P-values are adjusted for multiple comparisons for PFS.
Related Topics
Concepts
Olaparib
Bevacizumab
Medicine
Durvalumab
Oncology
Ovarian cancer
Internal medicine
Cisplatin
Combination therapy
Chemotherapy
Cancer
Nivolumab
Immunotherapy
Poly ADP ribose polymerase
Chemistry
Polymerase
Biochemistry
Gene
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/1078-0432.29313370
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4411285026
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4411285026Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1078-0432.29313370Digital Object Identifier
- Title
-
Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 TrialWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-06-13Full publication date if available
- Authors
-
Jung‐Min Lee, Austin Miller, Peter G. Rose, Mariam AlHilli, Christina Washington, Veena S. John, Chirag A. Shah, Koji Matsuo, Jean Siedel, David S. Miller, Elizabeth Hopp, Andrea O’Shea, John K. Chan, Leslie Bradford, Christopher B. Morse, Christa Nagel, Kerry J. Rodabaugh, Elise C. Kohn, Kathleen N. Moore, Joyce F. LiuList of authors in order
- Landing page
-
https://doi.org/10.1158/1078-0432.29313370Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1078-0432.29313370Direct OA link when available
- Concepts
-
Olaparib, Bevacizumab, Medicine, Durvalumab, Oncology, Ovarian cancer, Internal medicine, Cisplatin, Combination therapy, Chemotherapy, Cancer, Nivolumab, Immunotherapy, Poly ADP ribose polymerase, Chemistry, Polymerase, Biochemistry, GeneTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4411285026 |
|---|---|
| doi | https://doi.org/10.1158/1078-0432.29313370 |
| ids.doi | https://doi.org/10.1158/1078-0432.29313370 |
| ids.openalex | https://openalex.org/W4411285026 |
| fwci | 0.0 |
| type | preprint |
| title | Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T11914 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9919999837875366 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | PARP inhibition in cancer therapy |
| topics[1].id | https://openalex.org/T10550 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9819999933242798 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2743 |
| topics[1].subfield.display_name | Reproductive Medicine |
| topics[1].display_name | Ovarian cancer diagnosis and treatment |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2779962180 |
| concepts[0].level | 5 |
| concepts[0].score | 0.9286240935325623 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q7083106 |
| concepts[0].display_name | Olaparib |
| concepts[1].id | https://openalex.org/C2777802072 |
| concepts[1].level | 3 |
| concepts[1].score | 0.8176103234291077 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q413299 |
| concepts[1].display_name | Bevacizumab |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.7281166911125183 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2777742743 |
| concepts[3].level | 5 |
| concepts[3].score | 0.7157931327819824 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q19904005 |
| concepts[3].display_name | Durvalumab |
| concepts[4].id | https://openalex.org/C143998085 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6539491415023804 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[4].display_name | Oncology |
| concepts[5].id | https://openalex.org/C2780427987 |
| concepts[5].level | 3 |
| concepts[5].score | 0.6173774600028992 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q172341 |
| concepts[5].display_name | Ovarian cancer |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.5388486385345459 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C2778239845 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4859853684902191 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q412415 |
| concepts[7].display_name | Cisplatin |
| concepts[8].id | https://openalex.org/C2776999253 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4578411281108856 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1304270 |
| concepts[8].display_name | Combination therapy |
| concepts[9].id | https://openalex.org/C2776694085 |
| concepts[9].level | 2 |
| concepts[9].score | 0.38252928853034973 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[9].display_name | Chemotherapy |
| concepts[10].id | https://openalex.org/C121608353 |
| concepts[10].level | 2 |
| concepts[10].score | 0.26744556427001953 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[10].display_name | Cancer |
| concepts[11].id | https://openalex.org/C2780030458 |
| concepts[11].level | 4 |
| concepts[11].score | 0.24877026677131653 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7041828 |
| concepts[11].display_name | Nivolumab |
| concepts[12].id | https://openalex.org/C2777701055 |
| concepts[12].level | 3 |
| concepts[12].score | 0.13786864280700684 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[12].display_name | Immunotherapy |
| concepts[13].id | https://openalex.org/C182979987 |
| concepts[13].level | 4 |
| concepts[13].score | 0.10161343216896057 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q3907241 |
| concepts[13].display_name | Poly ADP ribose polymerase |
| concepts[14].id | https://openalex.org/C185592680 |
| concepts[14].level | 0 |
| concepts[14].score | 0.07081443071365356 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[14].display_name | Chemistry |
| concepts[15].id | https://openalex.org/C82381507 |
| concepts[15].level | 3 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q416878 |
| concepts[15].display_name | Polymerase |
| concepts[16].id | https://openalex.org/C55493867 |
| concepts[16].level | 1 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[16].display_name | Biochemistry |
| concepts[17].id | https://openalex.org/C104317684 |
| concepts[17].level | 2 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[17].display_name | Gene |
| keywords[0].id | https://openalex.org/keywords/olaparib |
| keywords[0].score | 0.9286240935325623 |
| keywords[0].display_name | Olaparib |
| keywords[1].id | https://openalex.org/keywords/bevacizumab |
| keywords[1].score | 0.8176103234291077 |
| keywords[1].display_name | Bevacizumab |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.7281166911125183 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/durvalumab |
| keywords[3].score | 0.7157931327819824 |
| keywords[3].display_name | Durvalumab |
| keywords[4].id | https://openalex.org/keywords/oncology |
| keywords[4].score | 0.6539491415023804 |
| keywords[4].display_name | Oncology |
| keywords[5].id | https://openalex.org/keywords/ovarian-cancer |
| keywords[5].score | 0.6173774600028992 |
| keywords[5].display_name | Ovarian cancer |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.5388486385345459 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/cisplatin |
| keywords[7].score | 0.4859853684902191 |
| keywords[7].display_name | Cisplatin |
| keywords[8].id | https://openalex.org/keywords/combination-therapy |
| keywords[8].score | 0.4578411281108856 |
| keywords[8].display_name | Combination therapy |
| keywords[9].id | https://openalex.org/keywords/chemotherapy |
| keywords[9].score | 0.38252928853034973 |
| keywords[9].display_name | Chemotherapy |
| keywords[10].id | https://openalex.org/keywords/cancer |
| keywords[10].score | 0.26744556427001953 |
| keywords[10].display_name | Cancer |
| keywords[11].id | https://openalex.org/keywords/nivolumab |
| keywords[11].score | 0.24877026677131653 |
| keywords[11].display_name | Nivolumab |
| keywords[12].id | https://openalex.org/keywords/immunotherapy |
| keywords[12].score | 0.13786864280700684 |
| keywords[12].display_name | Immunotherapy |
| keywords[13].id | https://openalex.org/keywords/poly-adp-ribose-polymerase |
| keywords[13].score | 0.10161343216896057 |
| keywords[13].display_name | Poly ADP ribose polymerase |
| keywords[14].id | https://openalex.org/keywords/chemistry |
| keywords[14].score | 0.07081443071365356 |
| keywords[14].display_name | Chemistry |
| language | en |
| locations[0].id | doi:10.1158/1078-0432.29313370 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1078-0432.29313370 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5067195409 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-1280-5909 |
| authorships[0].author.display_name | Jung‐Min Lee |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Jung-Min Lee |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5091066647 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-9739-8462 |
| authorships[1].author.display_name | Austin Miller |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Austin Miller |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5005911289 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-2676-0166 |
| authorships[2].author.display_name | Peter G. Rose |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Peter G. Rose |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5028471782 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-8494-5591 |
| authorships[3].author.display_name | Mariam AlHilli |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Mariam AlHilli |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5032324484 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-2482-8860 |
| authorships[4].author.display_name | Christina Washington |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Christina Washington |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5103269808 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Veena S. John |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Veena S. John |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5114009461 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Chirag A. Shah |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Chirag A. Shah |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5000713007 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-6232-8701 |
| authorships[7].author.display_name | Koji Matsuo |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Koji Matsuo |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5081634480 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-2596-3634 |
| authorships[8].author.display_name | Jean Siedel |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Jean Siedel |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5037590677 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-8215-5887 |
| authorships[9].author.display_name | David S. Miller |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | David S. Miller |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5111833667 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-0577-0501 |
| authorships[10].author.display_name | Elizabeth Hopp |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Elizabeth E. Hopp |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5103711254 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Andrea O’Shea |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Andrea O’Shea |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5024129361 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-3379-6829 |
| authorships[12].author.display_name | John K. Chan |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | John K. Chan |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5058267031 |
| authorships[13].author.orcid | https://orcid.org/0000-0001-6954-6712 |
| authorships[13].author.display_name | Leslie Bradford |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Leslie S. Bradford |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5112413646 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-0155-4246 |
| authorships[14].author.display_name | Christopher B. Morse |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Christopher B. Morse |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5091294358 |
| authorships[15].author.orcid | https://orcid.org/0000-0001-6454-6246 |
| authorships[15].author.display_name | Christa Nagel |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Christa I. Nagel |
| authorships[15].is_corresponding | False |
| authorships[16].author.id | https://openalex.org/A5062355789 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-8884-7083 |
| authorships[16].author.display_name | Kerry J. Rodabaugh |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Kerry J. Rodabaugh |
| authorships[16].is_corresponding | False |
| authorships[17].author.id | https://openalex.org/A5005621340 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-8631-9762 |
| authorships[17].author.display_name | Elise C. Kohn |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Elise C. Kohn |
| authorships[17].is_corresponding | False |
| authorships[18].author.id | https://openalex.org/A5069337573 |
| authorships[18].author.orcid | https://orcid.org/0000-0002-5803-0718 |
| authorships[18].author.display_name | Kathleen N. Moore |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Kathleen N. Moore |
| authorships[18].is_corresponding | False |
| authorships[19].author.id | https://openalex.org/A5060953135 |
| authorships[19].author.orcid | https://orcid.org/0000-0003-3888-3972 |
| authorships[19].author.display_name | Joyce F. Liu |
| authorships[19].author_position | last |
| authorships[19].raw_author_name | Joyce F. Liu |
| authorships[19].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1078-0432.29313370 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11914 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9919999837875366 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | PARP inhibition in cancer therapy |
| related_works | https://openalex.org/W3112273539, https://openalex.org/W2188594974, https://openalex.org/W4361281158, https://openalex.org/W2944461583, https://openalex.org/W4389948617, https://openalex.org/W3136285682, https://openalex.org/W3112954044, https://openalex.org/W2792971967, https://openalex.org/W3040348061, https://openalex.org/W2903256743 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1078-0432.29313370 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1078-0432.29313370 |
| primary_location.id | doi:10.1158/1078-0432.29313370 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1078-0432.29313370 |
| publication_date | 2025-06-13 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.4 | 69 |
| abstract_inverted_index.= | 12 |
| abstract_inverted_index.a | 34 |
| abstract_inverted_index.(N | 11 |
| abstract_inverted_index.1. | 2 |
| abstract_inverted_index.by | 8, 25, 39 |
| abstract_inverted_index.to | 60 |
| abstract_inverted_index.vs | 44, 52 |
| abstract_inverted_index.95% | 62 |
| abstract_inverted_index.The | 54, 72 |
| abstract_inverted_index.and | 5, 46 |
| abstract_inverted_index.are | 31, 58, 74 |
| abstract_inverted_index.for | 21, 65, 76, 79 |
| abstract_inverted_index.no) | 45 |
| abstract_inverted_index.the | 18, 66 |
| abstract_inverted_index.(HR) | 30 |
| abstract_inverted_index.(yes | 43, 51 |
| abstract_inverted_index.PARP | 41 |
| abstract_inverted_index.no). | 53 |
| abstract_inverted_index.were | 15 |
| abstract_inverted_index.with | 33 |
| abstract_inverted_index.(CIs) | 57 |
| abstract_inverted_index.(PFS) | 24 |
| abstract_inverted_index.120). | 13 |
| abstract_inverted_index.model | 37 |
| abstract_inverted_index.prior | 40, 47 |
| abstract_inverted_index.Figure | 1 |
| abstract_inverted_index.Hazard | 28 |
| abstract_inverted_index.immune | 48 |
| abstract_inverted_index.method | 20 |
| abstract_inverted_index.ratios | 29 |
| abstract_inverted_index.hazards | 36 |
| abstract_inverted_index.overall | 6 |
| abstract_inverted_index.provide | 61 |
| abstract_inverted_index.P-values | 73 |
| abstract_inverted_index.adjusted | 59, 75 |
| abstract_inverted_index.coverage | 64 |
| abstract_inverted_index.multiple | 77 |
| abstract_inverted_index.original | 68 |
| abstract_inverted_index.survival | 4, 7, 23 |
| abstract_inverted_index.estimated | 16, 32 |
| abstract_inverted_index.inhibitor | 42, 50 |
| abstract_inverted_index.intervals | 56 |
| abstract_inverted_index.study’s | 67 |
| abstract_inverted_index.treatment | 10, 70 |
| abstract_inverted_index.utilizing | 17 |
| abstract_inverted_index.checkpoint | 49 |
| abstract_inverted_index.confidence | 55 |
| abstract_inverted_index.randomized | 9 |
| abstract_inverted_index.stratified | 38 |
| abstract_inverted_index.assessment. | 27 |
| abstract_inverted_index.comparisons | 78 |
| abstract_inverted_index.Kaplan-Meier | 19 |
| abstract_inverted_index.comparisons. | 71 |
| abstract_inverted_index.investigator | 26 |
| abstract_inverted_index.proportional | 35 |
| abstract_inverted_index.simultaneous | 63 |
| abstract_inverted_index.Distributions | 14 |
| abstract_inverted_index.PFS.</p> | 80 |
| abstract_inverted_index.Progression-free | 3 |
| abstract_inverted_index.progression-free | 22 |
| abstract_inverted_index.<p>Supplementary | 0 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 20 |
| citation_normalized_percentile.value | 0.32584432 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |